Novel ginsenosides 25-OH-PPD and 25-OCH 3 -PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action
Authors:
- 1 June 2009
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 278 (2) , 241-248
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapyJournal of Cellular and Molecular Medicine, 2009
- Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of ActionClinical Cancer Research, 2008
- Structure-Activity Relationship and Substrate-Dependent Phenomena in Effects of Ginsenosides on Activities of Drug-Metabolizing P450 EnzymesPLOS ONE, 2008
- Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?Drug Discovery Today, 2008
- 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of actionBritish Journal of Cancer, 2008
- Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 PathwayCancer Research, 2007
- Genistein, a Dietary Isoflavone, Down-Regulates the MDM2 Oncogene at Both Transcriptional and Posttranslational LevelsCancer Research, 2005
- Anti-diabetic effect of ginsenoside Re in ob/ob miceBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005
- Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone antisense oligonucleotides: In vitro and in vivo activities and mechanismsThe Prostate, 2002
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992